IQIRVO (elafibranor)
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONIST · PRIMARY BILIARY CHOLANGITIS
IPSEN BIOPHARMA
Drug class
Peroxisome Proliferator-Activated Receptor (PPAR) Agonist
Peroxisome proliferator-activated receptor (PPAR) agonists are a therapeutic drug class that binds to and activates one or more PPAR nuclear receptor isoforms—alpha, gamma, or delta—which function as transcription factors regulating cellular metabolism, inflammation, and energy homeostasis. Read more about Peroxisome Proliferator-Activated Receptor (PPAR) Agonist
2 drugs in this class 2 manufacturers
Drugs in Peroxisome Proliferator-Activated Receptor (PPAR) Agonist
LIVDELZI (seladelpar lysine)
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONIST · PRIMARY BILIARY CHOLANGITIS
GILEAD SCIENCES
Filter & compare in the drug finder →
Opens the drug finder with Peroxisome Proliferator-Activated Receptor (PPAR) Agonist preselected. Add indication or manufacturer filters there.
Peroxisome proliferator-activated receptor (PPAR) agonists are a therapeutic drug class that binds to and activates one or more PPAR nuclear receptor isoforms—alpha, gamma, or delta—which function as transcription factors regulating cellular metabolism, inflammation, and energy homeostasis.
By modulating target gene expression, these agents improve insulin sensitivity, stimulate fatty acid oxidation, lower circulating triglycerides, or reduce hepatic bile acid toxicity.
Clinically, members of this class are utilized to manage type 2 diabetes mellitus (via PPAR-gamma agonism), dyslipidemia and severe hypertriglyceridemia (via PPAR-alpha agonism), and cholestatic liver disease such as primary biliary cholangitis (via PPAR-delta or pan/dual-PPAR agonism).
-
fda.gov
Peroxisome proliferator-activated receptor (PPAR) agonists are a therapeutic drug class that binds to and activates one or more PPAR nuclear receptor isoforms—alpha, gamma, or delta—which function as transcription factors regulating cellular metabolism, inflammation, and energy homeostasis By modulating target gene expression, these agents improve insulin sensitivity, stimulate fatty acid oxidation, lower circulating triglycerides, or reduce hepatic bile acid toxicity Clinically, members of this...
-
fda.gov
Peroxisome proliferator-activated receptor (PPAR) agonists are a therapeutic drug class that binds to and activates one or more PPAR nuclear receptor isoforms—alpha, gamma, or delta—which function as transcription factors regulating cellular metabolism, inflammation, and energy homeostasis By modulating target gene expression, these agents improve insulin sensitivity, stimulate fatty acid oxidation, lower circulating triglycerides, or reduce hepatic bile acid toxicity Clinically, members of this...
-
nih.gov
Peroxisome proliferator-activated receptor (PPAR) agonists are a therapeutic drug class that binds to and activates one or more PPAR nuclear receptor isoforms—alpha, gamma, or delta—which function as transcription factors regulating cellular metabolism, inflammation, and energy homeostasis By modulating target gene expression, these agents improve insulin sensitivity, stimulate fatty acid oxidation, lower circulating triglycerides, or reduce hepatic bile acid toxicity
-
nih.gov
Peroxisome proliferator-activated receptor (PPAR) agonists are a therapeutic drug class that binds to and activates one or more PPAR nuclear receptor isoforms—alpha, gamma, or delta—which function as transcription factors regulating cellular metabolism, inflammation, and energy homeostasis
-
fda.gov
By modulating target gene expression, these agents improve insulin sensitivity, stimulate fatty acid oxidation, lower circulating triglycerides, or reduce hepatic bile acid toxicity Clinically, members of this class are utilized to manage type 2 diabetes mellitus (via PPAR-gamma agonism), dyslipidemia and severe hypertriglyceridemia (via PPAR-alpha agonism), and cholestatic liver disease such as primary biliary cholangitis (via PPAR-delta or pan/dual-PPAR agonism)
-
fda.gov
Clinically, members of this class are utilized to manage type 2 diabetes mellitus (via PPAR-gamma agonism), dyslipidemia and severe hypertriglyceridemia (via PPAR-alpha agonism), and cholestatic liver disease such as primary biliary cholangitis (via PPAR-delta or pan/dual-PPAR agonism)
-
nih.gov
Clinically, members of this class are utilized to manage type 2 diabetes mellitus (via PPAR-gamma agonism), dyslipidemia and severe hypertriglyceridemia (via PPAR-alpha agonism), and cholestatic liver disease such as primary biliary cholangitis (via PPAR-delta or pan/dual-PPAR agonism)
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.